DPP4 and angioedema: The case reports of gliptin-associated angioedema, even if limited in number, seem to suggest that this event can occur during treatment with DPP-IV inhibitors as monotherapy or combined with ACEIs, although the role of other drugs and additional risk factors cannot be excluded and deserves further investigations.